iNova Pharmaceuticals announces the launch of iPitch 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.
iPitch is a collaborative crowdsourcing program that allows product and packaging developers, innovators, licensors and certified manufacturers to connect with iNova and share their great ideas for healthcare products that have the potential for commercialisation.
It provides a wonderful opportunity for anyone with new and different ideas or next-generation solutions that may not have the resources or expertise to bring their innovations to market, or just looking for a commercialisation partner.
According to iNova Executive Director and Head of Innovation, Filomena Maiese, “We know there’s consumer health product innovations out there that haven’t yet been commercialised. We want to partner with them.”
iPitch specifically looks for effective, evidence-based products with innovative and new formats and formulations. After creating a lot of buzz last year, and by leveraging the power of global connectivity, the 2019 iPitch received hundreds of different and diverse product and formulation ideas from around the world. iNova is currently preparing to launch two of these products into the marketplace, which otherwise would not have had a chance to make it to consumers.
Entries for iPitch can be made according to criteria set out by iNova within a range of set ‘challenges’. This year, iNova has created and carefully selected a diverse set of challenges across which submissions can be made. This provides more opportunity for innovators to submit entries and captures ideas across a wide range of consumer healthcare needs. The challenges cover products from pregnancy supplements to packaging to face masks to cough, cold and flu formulations.
iNova is excited about building a number of new mutually beneficial business partnerships through iPitch. According to Chief Executive Officer, Dan Spira, “iNova has a strong track record of acquiring, building and launching trusted consumer healthcare brands, which makes us a great partner of choice for product owners and licensors globally”.
iNova has a diverse range of market-leading products. They have a trusted reputation among consumers and healthcare professionals and are recognised as an innovative partner of choice in the healthcare industry. With a multi-national business platform, it offers access to well-established operating platforms and broad distribution networks across Asia, Africa and ANZ.
iPitch will be open for applications for 12 weeks, ending 21 August 2020.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance